When Eli Lilly snapped up Scorpion Therapeutics’ PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new entity that would house its preclinical pipeline. | Antares may be forging ahead with Scorpion’s leadership team, but the company is adopting a different approach designed to account for the drastic transformation in both the biotech and macroeconomic environments.
Source: US biotechs must adapt as global competition rises: Antares CEO | Fierce Biotech
